29578-83-4

Basic information

• Product Name: 1-BROMO-3-METHOXY-5-METHYLBENZENE
• Synonyms: 3-Methyl-5-methoxyphenyl bromide;5-Bromo-3-methoxytoluene;3-BROMO-5-METHOXYTOLUENE;1-BROMO-3-METHOXY-5-METHYLBENZENE;1-Bromo-3-methoxy-5-methylbenzene 3-bromo-5-methoxytoluene;3-Bromo-5-methylanisole;1-Bromo-5-methoxy-3-methylbenzene
• CAS NO: 29578-83-4
• Molecular Formula: C₈H₉BrO
• Molecular Weight: 201.06
• Product Categories: Aromatic Halides (substituted);Aromatics Compounds;Aromatics
• Mol File: 29578-83-4.mol

Chemical Properties

• Melting Point: 52℃
• Boiling Point: 228℃
• Flash Point: 103℃
• Appearance: colorless oil
• Density: 1.378
• Vapor Pressure: 0.111mmHg at 25°C
• Refractive Index: 1.5560-1.5600
• Storage Temp.: Refrigerator
• CAS DataBase Reference: 1-BROMO-3-METHOXY-5-METHYLBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-3-METHOXY-5-METHYLBENZENE(29578-83-4)
• EPA Substance Registry System: 1-BROMO-3-METHOXY-5-METHYLBENZENE(29578-83-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 29578-83-4(Hazardous Substances Data)

Usage

Chemical Properties

Colorless Oil

InChI:InChI=1/C8H9BrO/c1-6-3-7(9)5-8(4-6)10-2/h3-5H,1-2H3

Upstream product

• 74204-00-5 3-bromo-5-methylphenol 
• 77-78-1 dimethyl sulfate 
• 66584-31-4 3-methoxy-5-methylphenylamine 
• 348169-39-1 4-bromo-2-methoxy-6-methyl-phenylamine 
• 1357103-83-3 C₈H₈BrN₂O⁽¹⁺⁾*Cl^(1-) 
• 50868-73-0 2-methoxy-6-methylbenzeneamine 
• 58169-99-6 2,3,4,6-tetrabromo-5-methyl-phenol 
• 108-39-4 3-methyl-phenol 
• 82477-66-5 1-chloro-3-methoxy-5-methylbenzene 
• 74137-36-3 3,5-dibromoanisole 
• 74-88-4 methyl iodide 
• 1611-92-3 3,5-dibromotoluene 
• 849062-36-8 (3-bromo-5-methylphenyl)boronic acid 

Downstream Products

• 29578-84-5 3-Methoxy-5-methylpropiophenon 
• 88-40-4 2-tert-butyl-5-methylanisole 
• 874-63-5 3,5-dimethylmethoxybenzene 
• 171102-68-4 2-fluoro-6-[(3-methyl-5-methoxyphenyl)thio]benzonitrile 
• 1019984-16-7 (3-methoxy-5-methyl-phenyl)-phenyl-methanol 
• 1019984-29-2 1-(3-methoxy-5-methyl-phenyl)-2-(4-methoxy-phenyl)-ethanone 
• 473923-98-7 3-methoxy-5-methylbenzonitrile 
• 66623-68-5 3-methoxy-5-methylsulfanyl-toluene 
• 1158949-11-1 3-methoxy-5-methyl-N-(pyridin-2-ylmethyl)benzamide 
• 123018-27-9 2-(3-bromo-5-methoxyphenyl)acetonitrile 
• 1220694-87-0 8-bromo-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 725251-81-0 (5-methoxy-3-methylphenyl)boronic acid 

Relevant articles and documents

Preparation process for 3-methyl-5-methoxybenzenesulfonyl chloride

The invention discloses a preparation process for 3-methyl-5-methoxybenzenesulfonyl chloride. The process comprises the following steps: 3,5-dibromotoluene is used as an initial raw material, the 3,5-dibromotoluene is subjected to a boronic acidification reaction, thus 3-methyl-5-bromophenylboronic acid is obtained, the 3-methyl-5-bromophenylboronic acid is subjected to an oxidation reaction, thus 3-methyl-5-bromophenol is obtained, the 3-methyl-5-bromophenol is subjected to a substitution reaction, thus 3-methyl-5-bromoanisoles is obtained, the 3-methyl-5-bromoanisoles is subjected to sulfonation, thus 3-methyl-5-methoxybenzenesulfonate is obtained, the 3-methyl-5-methoxybenzenesulfonate is subjected to a substitution reaction, and therefore the objective compound 3-methyl-5-methoxybenzenesulfonyl chloride is obtained. According to the above route, the raw materials are easy to obtain, post-treatment is simple, convenient and easy to implement, a yield is relatively high, and the process has relatively-good application value.

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The inventi

17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES

The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases.The invention further relates to suitable inhibitors and to a method for the production thereof.

NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

RENIN INHIBITORS

Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in the specification, and wherein either the bond between the C1and C2 carbon atoms is a double bond or the bond between the C2 and C3 carbon atoms is a double bond, R2 being absent when the bond between the C1 and C2 carbon atoms is a double bond.

SHIP 1 MODULATOR COMPOUNDS

The present invention provides the use of pelorol analogs of Formula, ( I ) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prop

A short and concise asymmetric synthesis of hamigeran B

The interesting biological properties of the hamigerans wherein hamigeran B is a potent antiviral agent with low cytotoxicity to host cells make these deceptively simple looking structures challenging synthetic targets. A strategy to hamigeran B evolved wherein the three contiguous stereocenters are established ultimately from a Pd catalyzed asymmetric allylic alkylation (AAA). The latter involves an asymmetric allylation of a non-stabilized ketone enolate in 77% yield and 93% ee. By using this process, (S)-5-allyl-2-isopropyl-5- methyl-1-trifluoromethanesulfonyloxycyclopentene becomes available in four steps from 2-methylcyclopentanone. Introduction of the aryl unit by cross-coupling proceeded intermolecularly but failed intramolecularly. On the other hand, reductive removal of the triflate permitted a Heck reaction to effect intramolecular introduction of the aryl ring. The unusual conformational properties of this molecular architecture are revealed by the regioselectivity of the β-hydrogen elimination in the Heck reaction and the diastereoselectivity of the reduction establishing the stereochemistry of the carbon bearing the isopropyl group. The successful route consists of 15 steps from 2-methylcyclopentanone and dimethylorcinol illustrating the efficiency of the route based upon the Pd AAA.